- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00176475
Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease
A Pilot Study of Irradiated HLA-Partially Matched Allogeneic Related Donor Lymphocytes in Conjunction With Rituximab for Selected Patients With CD20 + Malignancies
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving irradiated donor lymphocytes together with rituximab may kill more cancer cells.
PURPOSE: This clinical trial is studying the side effects and how well giving irradiated donor lymphocytes together with rituximab works in treating patients with relapsed or refractory lymphoproliferative disease.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
OBJECTIVES:
Primary
- Determine the toxicity of irradiated HLA-partially matched related donor lymphocytes when administered with rituximab in patients with relapsed or refractory CD20-positive lymphoproliferative disease.
- Determine the efficacy of this regimen in these patients.
Secondary
- Correlate response with Fc receptor FcγIIIA polymorphisms or predicted HLA-directed natural killer cell reactivity.
OUTLINE: This is a pilot study.
- Rituximab therapy: Patients receive rituximab IV on days -1, 6, 13, and 20. Treatment repeats approximately every 4 months in the absence of disease progression or unacceptable toxicity.
- Donor lymphocyte infusion: Patients receive irradiated donor lymphocytes IV over 1 hour on day 0. Treatment repeats every 8-16 weeks (alternating with courses of rituximab therapy) for up to 6 donor lymphocyte infusions in the absence of disease progression or unacceptable toxicity.
Peripheral blood is collected periodically during study for correlative laboratory studies. Blood samples are analyzed for FcγIIIA polymorphism by fluorescent in situ hybridization or by reverse transcriptase-polymerase chain reaction. Survival of donor lymphocytes is assessed by chimerism studies.
PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
New Jersey
-
New Brunswick, New Jersey, Förenta staterna, 08903
- Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
DISEASE CHARACTERISTICS:
Histologically confirmed lymphoproliferative disease
- CD20-positive disease
- Bidimensionally measurable disease OR abnormal cells detected in blood
Resistant or refractory to standard therapies and/or unlikely to benefit from additional standard therapies* AND meets 1 of the following criteria:
Disease with anticipated response rate < 20% after treatment with rituximab alone, including any of the following:
- Diffuse large cell lymphoma
- B-cell lymphoblastic lymphoma
- Burkitt's lymphoma
- Acute lymphocytic leukemia
Relapsed or progressive disease after prior treatment with rituximab, including any of the following:
- Hodgkin's lymphoma
- Hairy cell leukemia
Chronic lymphocytic leukemia/small lymphocytic lymphoma meeting any of the following criteria:
- Received prior fludarabine phosphate-containing regimens and relapsed within 1 year of treatment OR ineligible to receive such therapy due to comorbidities or allergies
- Received prior anti-CD52 monoclonal antibody therapy and relapsed within 1 year of treatment OR ineligible to receive such therapy (for patients without symptomatic lymphadenopathy)
- Has documentation of disease-associated symptoms, rapid disease progression, or other indications for treatment
B-cell prolymphocytic leukemia meeting any of the following criteria:
- Received prior fludarabine phosphate- or alkylating agent-containing regimens and relapsed within 1 year of treatment OR ineligible to receive such therapy due to comorbidities or allergies
- Received prior anti-CD52 monoclonal antibody therapy OR ineligible to receive such therapy (for patients without symptomatic lymphadenopathy)
Lymphoplasmacytic lymphoma, marginal zone lymphoma, mucosa-associated lymphoid tissue lymphoma, or follicular lymphoma meeting any of the following criteria:
- Received prior fludarabine phosphate- and/or alkylating agent-containing regimens and relapsed within 1 year of treatment OR ineligible to receive such therapy due to comorbidities or allergies
- Received prior anti-CD20 monoclonal antibody therapy and relapsed within 1 year of treatment OR ineligible to receive such therapy
- Received prior radioconjugated anti-CD20 monoclonal antibody therapy OR ineligible to receive such therapy
- Has documentation of disease-associated symptoms, rapid disease progression, or other indications for treatment
Multiple myeloma meeting any of the following criteria:
- Received prior alkylating agent-, thalidomide-, corticosteroid-, or bortezomib-containing regimens and relapsed after 1 year of treatment OR ineligible to receive such therapies due to comorbidities or allergies
- Received prior high-dose chemotherapy followed by autologous hematopoietic stem cell rescue and relapsed after treatment OR ineligible to receive such therapy
Mantle cell lymphoma meeting the following criteria:
- Received prior combination chemotherapy and anti-CD20 monoclonal antibody therapy and relapsed after treatment OR ineligible to receive such therapy
Diffuse large B-cell lymphoma meeting any of the following criteria:
- Received prior combination chemotherapy and relapsed after treatment OR ineligible to receive such therapy
- Received prior salvage combination chemotherapy with or without high-dose chemotherapy followed by autologous hematopoietic stem cell rescue and relapsed after treatment OR not a candidate to receive such therapy
- Received prior radiolabeled anti-CD20 monoclonal antibody therapy for transformed large cell lymphoma OR ineligible to receive such therapy
Burkitt's lymphoma meeting any of the following criteria:
- Received prior combination chemotherapy and relapsed after treatment OR ineligible to receive such therapy
- Received prior salvage combination chemotherapy with or without high-dose chemotherapy followed by autologous hematopoietic stem cell rescue and relapsed after treatment OR ineligible to receive such therapy
Lymphomatoid granulomatosis meeting any of the following criteria:
- Received prior single-agent or combination chemotherapy and relapsed after treatment OR ineligible to receive such therapy
- Has documentation of disease-associated symptoms, rapid disease progression, or other indications for treatment
Acute lymphocytic leukemia meeting any of the following criteria:
- Received prior multi-agent combination chemotherapy administered in sequential induction, consolidation, and maintenance courses and relapsed during or after treatment OR ineligible to receive such therapy
- Received prior chemotherapy with or without radiotherapy followed by allogeneic hematopoietic stem cell transplantation (HSCT) and relapsed after treatment OR not a candidate for such therapy
- Received prior treatment with chemotherapy with or without radiotherapy followed by allogeneic HSCT and relapsed after treatment (or not a candidate for such therapy) AND demonstrates persistent cytogenetic, fluorescent in situ hybridization, or molecular (reverse transcriptase-polymerase chain reaction) evidence of the bcr-abl fusion gene despite 6 weeks of treatment with imatinib mesylate NOTE: *Not eligible to receive standard available salvage regimens anticipated to result in durable remission
- No active CNS malignancy
- Not considered a candidate for allogeneic HSCT
- HLA-partially matched (≥ 2/6) related donor available
PATIENT CHARACTERISTICS:
- ECOG performance status 0-1
- Life expectancy > 3 months
- Not pregnant
- Negative pregnancy test
- Fertile women must use effective contraception
- Bilirubin < 1.5 times upper limit of normal (ULN)
- AST < 3.0 times ULN
- Cardiac ejection fraction > 35%
- Absolute neutrophil count > 1,000/mm³ (without cytokines)
- Platelet count > 50,000/mm³ (untransfused)
- No significant organ dysfunction
- No active uncontrolled infections
- No hypersensitivity reaction to rituximab that has precluded completion of a 4-week course of rituximab therapy
- No uncontrolled psychiatric illness or medical condition that would preclude tolerance of study treatment
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- Recovered from prior therapy for at least 7 days
- More than 30 days since prior cytotoxic chemotherapy
- At least 14 days since prior steroids
- At least 14 days since prior radiotherapy to non-target lesions
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Therapeutic allogeneic lymphocytes with rituximab
|
Patients will receive a single day infusion of standard dose rituximab (375 mg/m2) on days -1, 6, 13, 20 approximately every 4 months (in conjunction with alternating doses of the lymphocyte infusion).
The product will then be assigned to the specific patient and the released product will be transported to and administered to the patient at CINJ, after premedication of the patient with acetaminophen 650 mg PO and diphenhydramine- HCl 25 mg PO.
Blood product administration will be every 8 weeks and undertaken according to CINJ standard procedures
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Toxicity as assessed by NCI CTCAE v3.0
Tidsram: 4 years
|
4 years
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Efficacy
Tidsram: 4 years
|
4 years
|
Samarbetspartners och utredare
Samarbetspartners
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
- stadium III vuxen diffust storcelligt lymfom
- stadium III vuxen Burkitt lymfom
- stadium IV grad 3 follikulärt lymfom
- stadium IV vuxen diffust storcelligt lymfom
- stadium IV vuxen Burkitt lymfom
- återkommande follikulärt lymfom grad 3
- återkommande vuxen diffust storcelligt lymfom
- återkommande vuxen Burkitt lymfom
- återkommande vuxen Hodgkin-lymfom
- Waldenström makroglobulinemi
- stadium III grad 1 follikulärt lymfom
- stadium III grad 2 follikulärt lymfom
- stadium III grad 3 follikulärt lymfom
- stadium IV grad 1 follikulärt lymfom
- stadium IV grad 2 follikulärt lymfom
- stadium III mantelcellslymfom
- stadium IV mantelcellslymfom
- stadium II multipelt myelom
- stadium III multipelt myelom
- återkommande follikulärt lymfom grad 1
- återkommande follikulärt lymfom grad 2
- återkommande lymfom i marginalzonen
- återkommande små lymfocytiska lymfom
- stadium III små lymfocytiska lymfom
- stadium III marginalzon lymfom
- stadium IV små lymfocytiska lymfom
- stadium IV marginalzon lymfom
- extranodal marginalzon B-cellslymfom i slemhinneassocierad lymfoid vävnad
- nodal marginalzon B-cells lymfom
- marginalzonens lymfom i mjälten
- återkommande lymfoblastiskt lymfom hos vuxna
- återkommande mantelcellslymfom
- refraktär kronisk lymfatisk leukemi
- stadium III kronisk lymfatisk leukemi
- stadium IV kronisk lymfatisk leukemi
- stadium III vuxen Hodgkin lymfom
- stadium IV vuxen Hodgkin lymfom
- stadium III vuxen lymfoblastiskt lymfom
- stadium IV vuxen lymfoblastiskt lymfom
- återkommande vuxen grad III lymfomatoid granulomatosis
- refraktärt multipelt myelom
- återkommande akut lymfatisk leukemi hos vuxna
- refraktär hårcellsleukemi
- prolymfocytisk leukemi
- progressiv hårcellsleukemi, initial behandling
Ytterligare relevanta MeSH-villkor
- Hjärt-kärlsjukdomar
- Kärlsjukdomar
- Immunsystemets sjukdomar
- Neoplasmer efter histologisk typ
- Neoplasmer
- Lymfoproliferativa störningar
- Lymfatiska sjukdomar
- Immunproliferativa störningar
- Hematologiska sjukdomar
- Hemorragiska störningar
- Hemostatiska störningar
- Paraproteinemier
- Blodproteinstörningar
- Lymfom
- Multipelt myelom
- Neoplasmer, Plasmacell
- Leukemi
- Plasmacytom
- Läkemedels fysiologiska effekter
- Antireumatiska medel
- Antineoplastiska medel
- Immunologiska faktorer
- Antineoplastiska medel, immunologiska
- Rituximab
Andra studie-ID-nummer
- CDR0000540171
- P30CA072720 (U.S.S. NIH-anslag/kontrakt)
- CINJ-010406 (Annan identifierare: Cancer Institute of New Jersey)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på rituximab
-
Children's Oncology GroupNational Cancer Institute (NCI)Aktiv, inte rekryterandeEBV-relaterad post-transplantation lymfoproliferativ störning | Monomorf post-transplantation lymfoproliferativ störning | Polymorf post-transplantation lymfoproliferativ störning | Återkommande monomorfisk post-transplantationslymfoproliferativ störning | Återkommande polymorf post-transplantation... och andra villkorFörenta staterna
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RekryteringAnn Arbor steg I grad 1 follikulärt lymfom | Ann Arbor steg I grad 2 follikulärt lymfom | Ann Arbor steg II grad 1 follikulärt lymfom | Ann Arbor steg II grad 2 follikulärt lymfomFörenta staterna
-
National Cancer Institute (NCI)AvslutadAnn Arbor steg III grad 1 follikulärt lymfom | Ann Arbor steg III grad 2 follikulärt lymfom | Ann Arbor steg IV grad 1 follikulärt lymfom | Ann Arbor steg IV grad 2 follikulärt lymfom | Ann Arbor steg II grad 3 sammanhängande follikulärt lymfom | Ann Arbor Steg II Grad 3 Non-Contiguous Follicular... och andra villkorFörenta staterna
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Aktiv, inte rekryterandeÅterkommande follikulärt lymfom grad 1 | Återkommande follikulärt lymfom grad 2 | Återkommande mantelcellslymfom | Återkommande lymfom i marginalzonen | Refraktärt B-cells non-Hodgkin-lymfom | Återkommande litet lymfocytiskt lymfom | Återkommande B-cells non-Hodgkin lymfom | Återkommande follikulärt... och andra villkorFörenta staterna
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, inte rekryterandeÅterkommande litet lymfocytiskt lymfom | Prolymfocytisk leukemi | Återkommande kronisk lymfatisk leukemiFörenta staterna
-
Mabion SAParexelIndragen
-
National Cancer Institute (NCI)Aktiv, inte rekryterandeÅterkommande mantelcellslymfom | Refraktärt B-cells non-Hodgkin-lymfom | Återkommande B-cells non-Hodgkin lymfom | Refraktärt mantelcellslymfomFörenta staterna
-
National Cancer Institute (NCI)Celgene CorporationAktiv, inte rekryterandeAnn Arbor steg III grad 1 follikulärt lymfom | Ann Arbor steg III grad 2 follikulärt lymfom | Ann Arbor steg IV grad 1 follikulärt lymfom | Ann Arbor steg IV grad 2 follikulärt lymfom | Ann Arbor steg II grad 3 sammanhängande follikulärt lymfom | Ann Arbor Steg II Grad 3 Non-Contiguous Follicular... och andra villkorFörenta staterna
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RekryteringKronisk lymfatisk leukemi/litet lymfocytiskt lymfomFörenta staterna
-
National Cancer Institute (NCI)Aktiv, inte rekryterandeSteg I Kronisk lymfatisk leukemi | Steg II Kronisk lymfatisk leukemi | Stadium III Kronisk lymfatisk leukemi | Steg IV Kronisk lymfatisk leukemiFörenta staterna, Kanada